Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital
BackgroundSodium-Glucose Co-Transporter 2 (SGLT2) inhibitors, known as Gliflozins, have demonstrated efficacy in managing type 2 diabetes mellitus (T2DM) and providing cardiovascular and renal benefits. Given the prevalence of diabetes, heart failure (HF), and chronic kidney disease (CKD) in the UAE...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1529528/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849737813729214464 |
|---|---|
| author | Wessa Shenouda Dixon Thomas Omar Nabi Seeba Zachariah |
| author_facet | Wessa Shenouda Dixon Thomas Omar Nabi Seeba Zachariah |
| author_sort | Wessa Shenouda |
| collection | DOAJ |
| description | BackgroundSodium-Glucose Co-Transporter 2 (SGLT2) inhibitors, known as Gliflozins, have demonstrated efficacy in managing type 2 diabetes mellitus (T2DM) and providing cardiovascular and renal benefits. Given the prevalence of diabetes, heart failure (HF), and chronic kidney disease (CKD) in the UAE, there is a need to evaluate the prescribing patterns of Gliflozins in these population. The objective of this study was to explore the relationship between Gliflozins use for patients who were admitted to the hospital at least once from 2021 to 2023 and different clinical factors.MethodsA retrospective medication review was conducted from 2021 to 2023 at tertiary-level care hospital in Ajman, UAE. Data were collected on prescribed Gliflozins, patient demographic information, BMI, HbA1c levels, and comorbidities (HF, CKD). Chi-square tests and binary logistic regression were used to explore associations between Gliflozin use and clinical factors.ResultsOut of the 255 patients’ data collected, Gliflozin use was significantly associated with obesity (p = 0.002), higher HbA1c levels (p < 0.001), and comorbidities, particularly HF (61.5% of HF patients) and CKD. The use of Gliflozins increased each year. Patients with HF were 8.03 times more likely to use Gliflozins, and those with diabetes were 6.86 times more likely, underscoring the multidimensional role of these medications.ConclusionGliflozin prescribing patterns in the UAE reflect global trends, with increased use among patients with diabetes, HF, and CKD. Further research is recommended to explore factors influencing prescription practices and optimize Gliflozin therapy if gliflozins use considerably increase in new diagnosis of diabetes and CKD even in mild conditions. |
| format | Article |
| id | doaj-art-6ee1c764b48342bcaf8106065e650d3c |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-6ee1c764b48342bcaf8106065e650d3c2025-08-20T03:06:48ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-04-011610.3389/fphar.2025.15295281529528Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospitalWessa Shenouda0Dixon Thomas1Omar Nabi2Seeba Zachariah3College of Pharmacy, Gulf Medical University, Ajman, United Arab EmiratesCollege of Pharmacy, Gulf Medical University, Ajman, United Arab EmiratesOperations, Thumbay University Hospital, Ajman, United Arab EmiratesCollege of Pharmacy, Gulf Medical University, Ajman, United Arab EmiratesBackgroundSodium-Glucose Co-Transporter 2 (SGLT2) inhibitors, known as Gliflozins, have demonstrated efficacy in managing type 2 diabetes mellitus (T2DM) and providing cardiovascular and renal benefits. Given the prevalence of diabetes, heart failure (HF), and chronic kidney disease (CKD) in the UAE, there is a need to evaluate the prescribing patterns of Gliflozins in these population. The objective of this study was to explore the relationship between Gliflozins use for patients who were admitted to the hospital at least once from 2021 to 2023 and different clinical factors.MethodsA retrospective medication review was conducted from 2021 to 2023 at tertiary-level care hospital in Ajman, UAE. Data were collected on prescribed Gliflozins, patient demographic information, BMI, HbA1c levels, and comorbidities (HF, CKD). Chi-square tests and binary logistic regression were used to explore associations between Gliflozin use and clinical factors.ResultsOut of the 255 patients’ data collected, Gliflozin use was significantly associated with obesity (p = 0.002), higher HbA1c levels (p < 0.001), and comorbidities, particularly HF (61.5% of HF patients) and CKD. The use of Gliflozins increased each year. Patients with HF were 8.03 times more likely to use Gliflozins, and those with diabetes were 6.86 times more likely, underscoring the multidimensional role of these medications.ConclusionGliflozin prescribing patterns in the UAE reflect global trends, with increased use among patients with diabetes, HF, and CKD. Further research is recommended to explore factors influencing prescription practices and optimize Gliflozin therapy if gliflozins use considerably increase in new diagnosis of diabetes and CKD even in mild conditions.https://www.frontiersin.org/articles/10.3389/fphar.2025.1529528/fullGliflozinsSGLT2 inhibitorsdrug utilizationdiabetes mellitusheart failurechronic kidney disease |
| spellingShingle | Wessa Shenouda Dixon Thomas Omar Nabi Seeba Zachariah Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital Frontiers in Pharmacology Gliflozins SGLT2 inhibitors drug utilization diabetes mellitus heart failure chronic kidney disease |
| title | Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital |
| title_full | Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital |
| title_fullStr | Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital |
| title_full_unstemmed | Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital |
| title_short | Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital |
| title_sort | assessment of gliflozins prescribing pattern in a united arab emirates tertiary level care hospital |
| topic | Gliflozins SGLT2 inhibitors drug utilization diabetes mellitus heart failure chronic kidney disease |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1529528/full |
| work_keys_str_mv | AT wessashenouda assessmentofgliflozinsprescribingpatterninaunitedarabemiratestertiarylevelcarehospital AT dixonthomas assessmentofgliflozinsprescribingpatterninaunitedarabemiratestertiarylevelcarehospital AT omarnabi assessmentofgliflozinsprescribingpatterninaunitedarabemiratestertiarylevelcarehospital AT seebazachariah assessmentofgliflozinsprescribingpatterninaunitedarabemiratestertiarylevelcarehospital |